COVID-19. COVID-19 disease
Conditions
Interventions
Intervention 1: Intervention group 1: Patients in the tocilizumab group will receive two doses of 400 mg of tocilizumab(temziva, AryoGen Pharmed) every 24 hours. Intervention 2: Intervention group 2:
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 68 Years
Inclusion criteria
Inclusion criteria: All patients with Coronavirus disease (COVID-19) admitted to intensive care units diagnosis of Covid-19 based on Polymerase chain reaction (PCR) of nasopharyngeal Serum C-reactive protein (CRP) and interleukin 6 levels are at least twice normal Oxygen saturation (o2sat) more than 80% without supplemental oxygen or Respiratory Rate (RR) more than 24
Exclusion criteria
Exclusion criteria: History of drug allergy Platelets less than 50000 Suspected by active viral (Non-COVID), bacterial and fungal infections Primary intubation absolute neutrophil count (ANC) less than 500 Any clinical suspicion of gastrointestinal obstruction Pregnancy and lactation Patient or family dissatisfaction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: daily until discharge. Method of measurement: medical record.;Need for mechanical ventilation. Timepoint: daily until discharge. Method of measurement: medical record.;Oxygenation rate. Timepoint: daily until discharge. Method of measurement: medical record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of days hospitalized in the intensive care unit. Timepoint: Daily until discharge. Method of measurement: medical record.;Duration of hospitalization. Timepoint: Daily until discharge. Method of measurement: medical record.;Inflammatory biomarkers (ferritin, LDH, IL6, CRP). Timepoint: Before and after all interventions. Method of measurement: ELIZA technique. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Gholinataj Jelodar
Yazd University of Medical Sciences
Outcome results
None listed